Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab versus benralizumab effects on resident and inflammatory eosinophils
NL-OMON49549Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of mepolizumab and benralizumab in asthma and eosinophilic asthma (EA) (2 cohorts), sponsored by University Medical Center Utrecht. Planned start Jun 2020; status: withdrawn.
02
Drugs
mepolizumabbenralizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON49549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49549.